In an interview with PharmaShots, Brandon Smith, Chief Business Officer at Prothena shared his views on Novo Nordisk's acquisition of Prothena's ATTR amyloidosis program includes PRX004Shots:The companies have entered into a definitive purchase agreement in which Novo Nordisk has acquired Prothena's PRX004 and broader ATTR amyloidosis programNovo Nordisk acquires Prothena's subsidiary and gets WW rights to the IP and…
